Literature DB >> 15456741

Cyclic exposure to hypoxia and reoxygenation selects for tumor cells with defects in mitochondrial apoptotic pathways.

Martin Weinmann1, Verena Jendrossek, Dilek Güner, Barbara Goecke, Claus Belka.   

Abstract

The negative influence of hypoxia on the outcome of malignant tumors may be caused by direct oxygen effects, and potentially, the selection of resistant tumor cells under repetitive hypoxia. To evaluate whether cyclic hypoxia selects for resistant cells and to analyze the underlying mechanisms, the influence of cyclic hypoxia on intracellular death pathways was determined in tumor cells. It could be demonstrated that cyclic hypoxia selects for cells with increased resistance against hypoxia-induced apoptosis. These cells exhibited a cross-resistance against paradigmatic triggers of mitochondrial apoptotic pathways (ionizing radiation/etoposide). In contrast, TRAIL-receptor mediated apoptosis remained unaffected. Thus, cyclic hypoxia selects for cells with defects of the mitochondrial rather than receptor-mediated pathways. Selection of p53-defective cells has been described as a consequence of cyclic hypoxia; therefore, we evaluated the impact of hypoxic selection on activation of p21 and downstream mediators of p53-dependent apoptosis. p53 function and protein levels of key mediators of mitochondrial apoptosis remained unaffected by hypoxic selection. However, radiation-induced conformational changes of Bax were reduced after cyclic hypoxia. In summary, it could be demonstrated that hypoxic stress confers a selection pressure on mitochondrial apoptotic pathways and, consecutively, to an increased resistance toward mitochondrial death triggers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15456741     DOI: 10.1096/fj.04-1918fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  23 in total

Review 1.  Tumor cell metabolism: an integral view.

Authors:  Susana Romero-Garcia; Jose Sullivan Lopez-Gonzalez; José Luis Báez-Viveros; Dolores Aguilar-Cazares; Heriberto Prado-Garcia
Journal:  Cancer Biol Ther       Date:  2011-12-01       Impact factor: 4.742

Review 2.  [Neurological complications of neurooncological therapy].

Authors:  U Herrlinger; J P Steinbach
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

3.  The proteasome inhibitor MG-132 protects hypoxic SiHa cervical carcinoma cells after cyclic hypoxia/reoxygenation from ionizing radiation.

Authors:  Frank Pajonk; Thorsten Grumann; William H McBride
Journal:  Neoplasia       Date:  2006-12       Impact factor: 5.715

4.  Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress.

Authors:  Jaime D Blais; Christina L Addison; Robert Edge; Theresa Falls; Huijun Zhao; Kishore Wary; Costas Koumenis; Heather P Harding; David Ron; Martin Holcik; John C Bell
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

Review 5.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.

Authors:  S R McKeown
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

6.  BH3 mimetics reactivate autophagic cell death in anoxia-resistant malignant glioma cells.

Authors:  Holger Hetschko; Valerie Voss; Christian Senft; Volker Seifert; Jochen H M Prehn; Donat Kögel
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

7.  Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis.

Authors:  Hong-li Yan; Geng Xue; Qian Mei; Yu-zhao Wang; Fei-xiang Ding; Mo-Fang Liu; Ming-Hua Lu; Ying Tang; Hong-yu Yu; Shu-han Sun
Journal:  EMBO J       Date:  2009-08-20       Impact factor: 11.598

Review 8.  Eco-evolutionary causes and consequences of temporal changes in intratumoural blood flow.

Authors:  Robert J Gillies; Joel S Brown; Alexander R A Anderson; Robert A Gatenby
Journal:  Nat Rev Cancer       Date:  2018-09       Impact factor: 60.716

9.  Intermittent hypoxia regulates stem-like characteristics and differentiation of neuroblastoma cells.

Authors:  Vasantha Kumar Bhaskara; Indra Mohanam; Jasti S Rao; Sanjeeva Mohanam
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

10.  Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy.

Authors:  Violetta Ritter; Franziska Krautter; Diana Klein; Verena Jendrossek; Justine Rudner
Journal:  Cell Death Dis       Date:  2021-07-13       Impact factor: 9.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.